Floatz logo

Mrx-2843

Pathologic Processes

Meryx, Inc.Phase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Pathologic Processes cohort.

Asset / SponsorPhaseRating
Guanfacine
Maimonides Medical Center
Phase 4BB
5-PYRIMIDINECARBOXAMIDE, 2-((1,1-DIMETHYLETHYL)AMINO)-4-(((1R,3R,4R)-3-HYDROXY-4-METHYLCYCLOHEXYL)AMINO)-
Celgene
Phase 2CCC
METAMIZOLE
Brigham and Women's Hospital
N/AD
VITAMIN D
Umm Al-Qura University
N/AD
Ocrevus
University of South Florida
D

View all 9 →

Same molecule, other indications

Mrx-2843 is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
cancerDormant
CC
Indicative ·
42 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →